Fractyl Health Inc.
(NASDAQ:GUTS) reported Wednesday one-year results from the Midpoint Cohort of its REMAIN-1 study, saying a single treatment with its investigational Revita DMR System helped patients maintain more of their GLP-1-induced weight loss than a sham procedure.
The clinical-stage metabolic therapeutics company said the latest findings reinforce Revita's potential as a durable procedural therapy for weight maintenance after discontinuing GLP-1 treatment.
Read Also: Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product Revita Demonstrates Durable Weight Maintenance In the modified intention-to-treat population of 45 participants, Revita reduced weight regain by about 40% versus the sham procedure after one year.
Patients treated with Revita experienced a least-squares mean weight regain of 7.8% of body weight compared with 13.0% in the sham group.
